Clarus Therapeutics Holdings, Inc. (CRXT) Stock Analysis
DELISTED 2022
What happened to Clarus Therapeutics Holdings, Inc. (CRXT) stock?
Clarus Therapeutics Holdings, Inc. (CRXT) no longer trades on public markets. It was delisted in September 2022. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- September 2022
- Last recorded price (historical):
- $0.0475 (last quote on record before the September 2022 delisting; historical, not a current quote)
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Clarus Therapeutics Holdings, Inc. (CRXT). Clarus Therapeutics Holdings, Inc. is a pharmaceutical company focused on oral testosterone replacement therapy. Their primary product, JATENZO, addresses hypogonadism in men, with licensing agreements exploring treatments for inflammatory breast disease and CoQ10 deficiencies.
Last analyzed: Mar 18, 2026Clarus Therapeutics Holdings, Inc. (CRXT) Healthcare & Pipeline Overview
More about this archive record
Can I still buy CRXT shares?
No. CRXT stopped trading on public markets in September 2022, so the shares are not available through a broker. Anything you see quoted for CRXT elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before CRXT stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Clarus Therapeutics Holdings, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.